Study #2023-0157
A randomized, open-label, phase 3 study of adjuvant Sacituzumab Govitecan and Pembrolizumab versus treatment of physician's choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
Description
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Triple Negative Breast Cancer
Study phase:
Phase III
Physician name:
Clinton Yam
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-866-254-1401
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.